Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Cisplatin and S-1 in Advanced Gastric Adenocarcinoma
NCT02370849Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2009
- Primary completion
- Feb 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in gastric adenocarcinoma (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 5 years. Started Oct 2009; status: completed.
02
Drugs
nimotuzumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02370849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370849.